Remarkable improvement in mitral valve regurgitation in paediatric eosinophilic granuloma with polyangiitis

AbstractWe report the case of a 12-year-old boy who presented with acute heart failure due to newly developed mitral valve regurgitation. The boy’s history combined with raised levels of inflammatory markers was suggestive of paediatric eosinophilic granuloma with polyangiitis. The echocardiographic course and rapid response to therapy are presented.

Download Full-text

Mitral regurgitation in Dachshund dogs without heart murmurs

Journal of Veterinary Research ◽

10.1515/jvetres-2017-0048 ◽

2017 ◽

Vol 61 (3) ◽

pp. 363-366

Author(s):

Magdalena Garncarz ◽

Marta Parzeniecka-Jaworska ◽

Magdalena Hulanicka ◽

Michał Jank ◽

Olga Szaluś-Jordanow ◽

...

Keyword(s):

Heart Failure ◽

Mitral Valve ◽

Mitral Regurgitation ◽

Mitral Valve Prolapse ◽

Mitral Valve Disease ◽

Mitral Valve Regurgitation ◽

Valve Disease ◽

Valve Regurgitation ◽

Heart Murmurs ◽

Few Data

Abstract Introduction: Older small breed dogs are considered at risk for heart failure secondary to chronic mitral valve disease. However, few data are available on the onset of this disease in such dogs. This study was performed to determine if auscultation alone can be used to eliminate clinically relevant mitral valve regurgitation seen in echocardiography in Dachshund dogs. Material and Methods: Clinical and echocardiographic data were obtained from 107 dogs without heart murmurs. Results: The study revealed that 63.6% of the dogs had mitral regurgitation. Numbers increased with age and a larger percentage of male Dachshunds were affected than female Dachshunds. Mitral valve prolapse and thickening were mild, and the regurgitant area inextensive in most dogs. Conclusions: The study shows that mitral valve regurgitation is prevalent (63.6%) in Dachshunds without heart murmurs. Typical lesions often become apparent during echocardiographic examinations in dogs under 5 years of age.

Download Full-text

Percutaneous repair of mitral valve regurgitation in patients with severe heart failure: comparison with optimal medical treatment

Acta Cardiologica ◽

10.1080/00015385.2017.1401275 ◽

2017 ◽

Vol 73 (4) ◽

pp. 378-386 ◽

Cited By ~ 8

Author(s):

Nicolas Geis ◽

Philip Raake ◽

Markus Lewening ◽

Derliz Mereles ◽

Emmanuel Chorianopoulos ◽

...

Keyword(s):

Heart Failure ◽

Mitral Valve ◽

Medical Treatment ◽

Severe Heart Failure ◽

Mitral Valve Regurgitation ◽

Valve Regurgitation ◽

Percutaneous Repair

Download Full-text

CRT and exercise capacity in heart failure: the impact of mitral valve regurgitation

EP Europace ◽

10.1093/europace/eun232 ◽

2008 ◽

Vol 10 (Supplement 3) ◽

pp. iii96-iii100 ◽

Cited By ~ 1

Author(s):

F. I. Parthenakis ◽

A. P. Patrianakos ◽

E. N. Simantirakis ◽

P. E. Vardas

Keyword(s):

Heart Failure ◽

Mitral Valve ◽

Exercise Capacity ◽

Mitral Valve Regurgitation ◽

Valve Regurgitation ◽

The Impact

Download Full-text

Acute Heart Failure in a Patient with Occult Barlow’s Disease Receiving Bevacizumab

Medicina ◽

10.3390/medicina57100998 ◽

2021 ◽

Vol 57 (10) ◽

pp. 998

Author(s):

Toshihide Izumida ◽

Teruhiko Imamura ◽

Yohei Ueno ◽

Kazuaki Fukahara ◽

Koichiro Kinugawa

Keyword(s):

Heart Failure ◽

Mitral Valve ◽

Acute Heart Failure ◽

Antihypertensive Agents ◽

Mitral Valve Regurgitation ◽

Barlow’S Disease ◽

Humanized Monoclonal Antibody ◽

Cardiology Clinic ◽

Prolapsed Mitral Valve

Bevacizumab is a recombinant humanized monoclonal antibody and a key drug for treatment of various types of cancer. Bevacizumab is associated with the occurrence of heart failure, but its risk factors remain unknown. A 55-year-old woman was diagnosed with cervical cancer, which was completely treated by bevacizumab-incorporated chemotherapy. During the 9-month bevacizumab therapy, she suffered from hypertension requiring multiple antihypertensive agents. She was admitted to our hospital due to acute heart failure with afterload mismatch and severe mitral regurgitation. A transesophageal echocardiography showed Barlow’s disease with a degenerated and widely prolapsed mitral valve. She received a scheduled surgical mitral valve repair. Post-operative cause was uneventful, but metastatic dissemination developed later. The existence of mitral valve regurgitation, even when sub-clinical, might be a risk of worsening heart failure during bevacizumab therapy. Careful follow-up at an onco-cardiology clinic is highly encouraged particularly for such a cohort during bevacizumab therapy.

Download Full-text

Impact of Mitral Valve Regurgitation Evaluated by Intraoperative Transesophageal Echocardiography on Long-Term Outcomes After Coronary Artery Bypass Grafting

Circulation ◽

10.1161/circulationaha.104.523472 ◽

2005 ◽

Vol 112 (9_supplement) ◽

Author(s):

Jacob N. Schroder ◽

Matthew L. Williams ◽

Jonathan A. Hata ◽

Lawrence H. Muhlbaier ◽

Madhav Swaminathan ◽

...

Keyword(s):

Heart Failure ◽

Mitral Valve ◽

Artery Bypass ◽

Mitral Valve Regurgitation ◽

Valve Regurgitation ◽

Heart Failure Hospitalization ◽

Intraoperative Transesophageal Echocardiography ◽

Cabg Patients

Background— It is unclear if mild or moderate mitral valve regurgitation (MR) should be repaired at the time of coronary artery bypass grafting (CABG). We sought to determine the long-term effect of uncorrected MR, measured by intraoperative transesophageal echocardiography (TEE), in CABG patients. Methods and Results— Between May 1999 and September 2003, data were gathered for 3264 consecutive patients who underwent isolated CABG and had MR graded by intraoperative TEE. MR was graded on the following 5 levels: none, trace, mild, moderate, and severe. Patients who had severe MR or who underwent mitral valve surgery were eliminated from the analysis. The remaining patients were combined into the following 3 groups: none or trace, mild, and moderate MR. Preoperative and follow-up data were 99% complete. The median length of follow-up was 3.0 years. Multivariable analysis controlling for important preoperative risk factors was performed to determine predictors of death and death/hospitalization for heart failure. Increasing MR was a risk factor for death [hazard ratio (HR), 1.44; P <0.001] and death/heart failure hospitalization (HR, 1.34; P <0.01). When patients with moderate MR were eliminated from the analysis, mild MR was a risk factor for death (HR, 1.34; P =0.011) and death/hospitalization for heart failure (HR, 1.34; P <0.001). Conclusions— Even mild MR, identified by intraoperative TEE, predicts worse outcomes after CABG. Revascularization alone did not eliminate the negative long-term effects of mild MR. CABG patients with uncorrected mild or moderate MR are at increased risk for death and heart-failure hospitalization; consideration for surgical repair or more aggressive medical management and follow-up is warranted.

Download Full-text